RXi to spin off RNAi and focus on targeted cancer therapies
This article was originally published in Scrip
RXi Pharmaceuticals, the Worcester, Massachusetts-based developer of targeted biotherapeutics, is to spin off its RNA interference therapy programmes to a new company and focus solely on its targeted cancer therapies. Both companies will be publicly traded, with the new RNAi business retaining the RXi name and the oncology-focused firm becoming Galena Biopharma. Concurrently, the firms will receive $12 million in financing from investors.
You may also be interested in...
Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.
AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.